Final Results of a Non-Interventional Study Evaluating the Quality of Life in Second-line Treatment of Metastatic Renal Cell Carcinoma With Everolimus: The EVERPRO Study

Autor:	Norbert Marschner, Christian Doehn, Anja Dietel, Katja Blumenstengel, Peter J. Goebell, Edwin Hermann, Anja Rogler, Marc-Oliver Grimm, Ulrich Kube, Lothar Bergmann, Michael Scheffler
Přispěvatelé:	University of Zurich
Rok vydání:	2019
Předmět:	Adult Male Oncology Cancer Research medicine.medical_specialty Bevacizumab medicine.medical_treatment Vascular Endothelial Growth Factor Receptor 2720 Hematology 610 Medicine & health Antineoplastic Agents Targeted therapy Young Adult 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma Internal medicine medicine Humans 1306 Cancer Research In patient Everolimus 030212 general & internal medicine Carcinoma Renal Cell Aged Aged 80 and over Second line treatment business.industry Hematology Middle Aged medicine.disease Kidney Neoplasms 10219 Clinic for Gastroenterology and Hepatology Treatment Outcome 030220 oncology & carcinogenesis Non interventional Quality of Life 2730 Oncology Female business medicine.drug
Zdroj:	Oncology Research and Treatment. 42:57-66
ISSN:	2296-5262 2296-5270
Popis:	Background: This study assessed the quality of life (QoL) and the implication of time effort of everolimus treatment in patients with metastatic renal cell carcinoma (mRCC). Methods: Adult patients with mRCC were eligible for everolimus treatment after first-line vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors or bevacizumab therapy. The primary end-point, QoL, was assessed by means of the NCCN-FACT FKSI-19 questionnaire. Results: In total, 202 patients (24% of female patients; median age, 71 years) were evaluable for QoL analyses. The median treatment duration was 4.4 months (95% CI, 3.8-5.3) and the median time to progression was 6 months (95% CI, 5.4-7.5). The median FKSI-19 total score remained stable during treatment (52.0 at therapy start, 55.0 at observation end). The median time effort spent on total therapy was 20 hours per patient. Most of the patients stated to have “no limitations,” “a little” or “moderate” limitations in their daily, social, and professional lives. Two months after the start of treatment, 65 patients reported none or a little time burden due to therapy. Conclusions: QoL was maintained during the everolimus therapy and limitations as well as time effort were acceptable for most of the patients. The study supports previous findings on switching mode of action after anti-VEGFR-targeted therapy to a mammalian target of rapamycin inhibitor.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6e5caf7c7719b672664facd1d3e5505 https://doi.org/10.1159/000494278 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.